Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-08-07

Clinical Trial Update: Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial evaluating oral rigosertib in myelofibrosis with anemia was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rigosertib (rigosertib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Myelofibrosis | Phase 2 | Status: TERMINATED | Results posted: 2020-08-07